BofA raised the firm’s price target on Cytokinetics (CYTK) to $64 from $63 and keeps a Neutral rating on the shares after the FDA approved aficamten as Myqorzo. Though calling Friday’s approval “a milestone for the company,” the firm views the decision and label as in-line with expectations and “thus unlikely to change the debate much,” the analyst tells investors.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $83 from $73 at Leerink
- Cytokinetics price target raised to $95 from $87 at RBC Capital
- Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating
- Cytokinetics price target raised to $99 from $95 at Goldman Sachs
- Cytokinetics price target raised to $88 from $78 at Citizens